170 related articles for article (PubMed ID: 9705602)
1. Antioxidants and mucosa protectives: realistic therapeutic options in inflammatory bowel disease?
Kruidenier L; Verspaget HW
Mediators Inflamm; 1998; 7(3):157-62. PubMed ID: 9705602
[TBL] [Abstract][Full Text] [Related]
2. Free radicals in inflammatory bowel diseases pathophysiology and therapeutic implications.
Gross V; Arndt H; Andus T; Palitzsch KD; Schölmerich J
Hepatogastroenterology; 1994 Aug; 41(4):320-7. PubMed ID: 7959565
[TBL] [Abstract][Full Text] [Related]
3. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
[TBL] [Abstract][Full Text] [Related]
4. Use of herbal preparations in the treatment of oxidant-mediated inflammatory disorders.
Kaplan M; Mutlu EA; Benson M; Fields JZ; Banan A; Keshavarzian A
Complement Ther Med; 2007 Sep; 15(3):207-16. PubMed ID: 17709066
[TBL] [Abstract][Full Text] [Related]
5. [Role of reactive oxygen metabolites in the pathogenesis of chronic inflammatory bowel disease].
Fernández-Bañares F
Gastroenterol Hepatol; 1995 Dec; 18(10):526-36. PubMed ID: 8548589
[No Abstract] [Full Text] [Related]
6. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease.
Erichsen K; Ulvik RJ; Grimstad T; Berstad A; Berge RK; Hausken T
Aliment Pharmacol Ther; 2005 Nov; 22(9):831-8. PubMed ID: 16225492
[TBL] [Abstract][Full Text] [Related]
7. Regulation of intestinal epithelial function: a link between opportunities for macromolecular drug delivery and inflammatory bowel disease.
Siccardi D; Turner JR; Mrsny RJ
Adv Drug Deliv Rev; 2005 Jan; 57(2):219-35. PubMed ID: 15555739
[TBL] [Abstract][Full Text] [Related]
8. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease.
Kruidenier L; Kuiper I; Van Duijn W; Mieremet-Ooms MA; van Hogezand RA; Lamers CB; Verspaget HW
J Pathol; 2003 Sep; 201(1):17-27. PubMed ID: 12950013
[TBL] [Abstract][Full Text] [Related]
9. Nutrition in inflammatory bowel disease.
Razack R; Seidner DL
Curr Opin Gastroenterol; 2007 Jul; 23(4):400-5. PubMed ID: 17545776
[TBL] [Abstract][Full Text] [Related]
10. [Redox homeostasis in inflammatory bowel diseases].
Blázovics A; Szentmihályi K; Prónai L; Hagymási K; Lugasi A; Kovács A; Fehér J
Orv Hetil; 2004 Jul; 145(28):1459-66. PubMed ID: 15366712
[TBL] [Abstract][Full Text] [Related]
11. Antioxidants and polyunsaturated fatty acids in multiple sclerosis.
van Meeteren ME; Teunissen CE; Dijkstra CD; van Tol EA
Eur J Clin Nutr; 2005 Dec; 59(12):1347-61. PubMed ID: 16118655
[TBL] [Abstract][Full Text] [Related]
12. Methods for the detection of antioxidants which prevent age related diseases: a critical review with particular emphasis on human intervention studies.
Hoelzl C; Bichler J; Ferk F; Simic T; Nersesyan A; Elbling L; Ehrlich V; Chakraborty A; Knasmüller S
J Physiol Pharmacol; 2005 Mar; 56 Suppl 2():49-64. PubMed ID: 16077190
[TBL] [Abstract][Full Text] [Related]
13. The implications of oxidative stress and antioxidant therapies in Inflammatory Bowel Disease: Clinical aspects and animal models.
Balmus IM; Ciobica A; Trifan A; Stanciu C
Saudi J Gastroenterol; 2016; 22(1):3-17. PubMed ID: 26831601
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy.
Kirkham P; Rahman I
Pharmacol Ther; 2006 Aug; 111(2):476-94. PubMed ID: 16458359
[TBL] [Abstract][Full Text] [Related]
15. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease.
Pashkow FJ; Watumull DG; Campbell CL
Am J Cardiol; 2008 May; 101(10A):58D-68D. PubMed ID: 18474276
[TBL] [Abstract][Full Text] [Related]
16. Effect of polyherbal formulation on experimental models of inflammatory bowel diseases.
Jagtap AG; Shirke SS; Phadke AS
J Ethnopharmacol; 2004 Feb; 90(2-3):195-204. PubMed ID: 15013181
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone in inflammatory bowel disease.
De Pascalis B; Bianchi A; Satta MA; Lupascu A; Mentella MC; Leo D; Fiore F; Fedeli P; Pontecorvi A; Pola P; Melina D; Gasbarrini A; De Marinis L; Armuzzi A
Eur Rev Med Pharmacol Sci; 2006; 10(1):13-6. PubMed ID: 16494105
[TBL] [Abstract][Full Text] [Related]
18. [Carbonyl groups content in serum proteins as an indicator of disease activity in children with inflammatory bowel diseases and its dependence on the other markers of inflammatory process].
Krzesiek E; Pytrus T; Kosmowska A; Iwańczak B
Pol Merkur Lekarski; 2008 Dec; 25(150):455-9. PubMed ID: 19205373
[TBL] [Abstract][Full Text] [Related]
19. A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis.
Agius LM
J Theor Biol; 2004 Mar; 227(2):219-28. PubMed ID: 14990386
[TBL] [Abstract][Full Text] [Related]
20. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
